changes observed are attributable to synergy among the 3 interventions or primarily to the CAL Skinsafe program.

Savina Aneja, BA
Angela K. Brimhall, DO, MS
Sanjay Aneja, BS
Douglas R. Kast, DO
Diana Carlson, DO
Kevin D. Cooper, MD
Jeremy S. Bordeaux, MD, MPH

Accepted for Publication: June 12, 2012.

Author Affiliations: Case Western Reserve University School of Medicine, Cleveland, Ohio (Ms Aneja and Drs Cooper and Bordeaux); Department of Dermatology (Drs Brimhall, Kast, Carlson, Cooper, and Bordeaux), Case Comprehensive Cancer Center (Drs Cooper and Bordeaux), Skin Diseases Research Center (Drs Cooper and Bordeaux), University Hospitals Case Medical Center, Cleveland; and Yale School of Medicine, New Haven, Connecticut (Mr Aneja).

Correspondence: Dr Bordeaux, Department of Dermatology, University Hospitals Case Medical Center, 11100 Euclid Ave, Lakeside 3500, Cleveland, OH 44124 (Jeremy.Bordeaux@uhhospitals.org).

Author Contributions: Ms Aneja and Drs Brimhall, Kast, Carlson, Cooper, and Bordeaux had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Brimhall, Cooper, and Bordeaux. Acquisition of data: Savina Aneja, Brimhall, Kast, and Carlson. Analysis and interpretation of data: Savina Aneja, Brimhall, Sanjay Aneja, Kast, Cooper, and Bordeaux. Drafting of the manuscript: Savina Aneja, and Kast. Critical revision of the manuscript for important intellectual content: Brimhall, Sanjay Aneja, Kast, Carlson, Cooper, and Bordeaux. Statistical analysis: Savina Aneja and Sanjay Aneja. Obtained funding: Cooper. Administrative, technical, and material support: Savina Aneja, Brimhall, Kast, and Cooper. Study supervision: Cooper and Bordeaux.

Financial Disclosure: Dr Bordeaux is supported by the Dermatology Foundation Clinical Career Development Award in Dermatologic Surgery.

Funding/Support: Dr Bordeaux is supported by the Dermatology Foundation Clinical Career Development Award in Dermatologic Surgery. This publication was made possible by the Case Western Reserve University Skin Diseases Research Center Grant Number P30AR039750 from National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Additional Information: Study No.: Case 1610. The trial protocol is available through the Case Western Reserve Cancer Center Institutional Review Board office.

Impact of Bar-Code Labeling of Clinical Photographs on Patient Care and Practice Workflow

Dermatologists rely on clinical photographs to observe lesions over time and to identify surgical sites. Studies have shown that without photographs at the time of surgery, patients could not identify 17% to 29% of biopsy sites, and surgeons could not identify 5% to 12% of biopsy sites. With photographs, all biopsy sites were identified.1,2

Accurate labeling and secure storage of clinical photographs is a universal problem within dermatology. From 2008 through 2011, our department used prints of clinical photographs stored in the patients' physical medical charts. Photographs were sometimes missing or unavailable at the various clinic sites, so we stored digital images on a secure server. Authorized users could access and print images at any site (2011). These methods were time intensive, error prone, and had less security than our online medical record.

Our practice uses demographic labels with a Code-39 bar code to identify patient specimens. Bar codes are a validated tool for error reduction in many areas of health care.3 We developed software (in C# for Windows Desktop) that uses photographs of these Code-39 bar-code labels to identify and upload clinical photographs into the patient's online medical record, enabling all providers to view these images. To format images for this software, we photograph the patient's demographic label prior to photographing the patient (the label with identifiers are not in the clinical photograph) (Figure).

Methods. At our academic medical center, for two 1-month periods, before (January 2010) and after (January 2012) implementation of the bar-code system, we assessed the proportion of Mohs surgery referrals with a photograph present in the medical record. To quantify the effort required under both our prior systems and the current bar-code system, we measured time for associated activities. We measured the time to log and process clinical photographs using our bar-code software to calculate the total administrative time per photograph. We compared this time to 2 prior systems that our practice used: (1) printing (Epson Photolab Personal) and labeling 2 copies of the digital photograph (for the medical chart and dermatologic surgeons); and (2) manually moving digital photographs onto a secure drive.

To determine the electronic readability of Code-39 barcode images obtained in our practice, we examined the demographic data extracted from 200 sequentially barcode images obtained during clinic visits. The Fischer exact test was used to determine P values for $2 \times 2$ frequency tables; the t test was used to compare group means.

Results. With our bar-code system, the percentage of patients with photographs available at the time of surgery increased from 84% (54 of 64) to 95% (73 of 77) ($P = .049$). Under the bar-code system, an average of 20 seconds of administrative time was required per clinical photograph, significantly faster than the 50 seconds per photograph needed.
Comment. Use of the bar-code system to process digital images significantly increased availability of photographs at the time of surgery and decreased the amount of administrative time required to archive and access photographs. Prior studies have demonstrated that photographs improve surgical site identification and patient care. Our software integrates photographs into the online medical record, which ensures the security of the clinical image and improves communication within a patient’s health care team.

Our software requires no new hardware and automates the labeling and processing of most photographs acquired (85%). In 15% of cases, because of poor lighting or focus, the software was unable to process the bar-code image, but no cases of partial or erroneous labeling were found. When a bar code is not read automatically, the data are entered manually. Use of 2-dimensional bar codes or a laser scanner would increase the accuracy of a bar-code system but would require substantial capital investment.

Incorrect identification of photographs is a medical error. To minimize this risk, a written log is kept with each camera. The log has the demographic label, body part photographed, and number of photographs taken. This takes 7 seconds per clinical photograph (11 seconds per patient with an average of 1.6 photographs per patient). This log is submitted with the memory cards to an administrator who uses the bar-code software to confirm the identity and process the photographs, which takes 13 seconds per clinical photograph.

Many dermatology practices use bar codes in labeling pathologic and laboratory specimens. Software that uses bar-code data to process photographs into a pdf report is a generalizable solution to a universal practice problem in dermatology.

Anthony R. Cukras, MD, PhD
Robert S. Stern, MD

Accepted for Publication: June 14, 2012.
Author Affiliations: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Correspondence: Dr Cukras, 330 Brookline Ave, GZ-5, Boston, MA 02215 (acukras@bidmc.harvard.edu).
Author Contributions: Dr Cukras had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Cukras and Stern. Acquisition of data: Cukras. Analysis and interpretation of data: Cukras and Stern. Drafting of the manuscript: Cukras. Critical revision of the manuscript for important intellectual content:

---

Table. Time to Archive a Single Photograph

<table>
<thead>
<tr>
<th>Method</th>
<th>Time Per Photograph, Mean (SD) (Range), sec</th>
</tr>
</thead>
<tbody>
<tr>
<td>New system, using bar-code–enabled software</td>
<td>20 (3) (18-32)</td>
</tr>
<tr>
<td>Old system</td>
<td><strong>77 (4) (70-80)</strong> a</td>
</tr>
<tr>
<td>Printing and labeling digital photographs</td>
<td>50 (20) (32-92) b</td>
</tr>
<tr>
<td>Manually renaming and moving photographs onto a secure drive</td>
<td></td>
</tr>
</tbody>
</table>

a P < .001 vs the new system.
b P = .001 vs the new system.
Stern. Statistical analysis: Stern. Administrative, technical, and material support: Stern. Study supervision: Stern. Conflict of Interest Disclosures: None reported.


COMMENTS AND OPINIONS

Interleukin 12/23 Agents and Major Adverse Cardiovascular Events

The JAMA article by Ryan et al1 on the association between biological therapies for psoriasis and cardiovascular events and the commentary by Bigby2 have generated significant controversy in the community of psoriasis researchers. By drawing attention to a potential increase in cardiovascular events in patients treated with interleukin (IL-)12/23 antagonists, the article and commentary provide a service to dermatologists and our patients.

The association between major adverse cardiovascular events and the use of IL-12/23 antagonists is unclear. The manufacturers of those drugs will never be able to escape the data in their pivotal trials: there were more adverse cardiovascular events in the treatment arms than in the placebo arms during the first 12 weeks of therapy.1 Was that a coincidence or is there a true risk of heart attack, arrhythmia, or stroke? Other trials do not confirm the association. In the phase 2 psoriatic arthritis trial of ustekinumab,3 there was a single myocardial infarction in the placebo arm but none in the group of subjects treated with ustekinumab. Several other placebo-controlled trials including approximately 1700 patients with psoriasis, psoriatic arthritis, or Crohn disease did not show an increase in major adverse cardiovascular events.3-6

Reich et al4 analyzed data on over 3000 ustekinumab study patients observed for up to 4 years and showed a decrease in heart attack or stroke compared with patients in 2 large databases, the Framingham Heart Study and a cohort of patients with moderate to severe psoriasis in the General Practice Research Database. These data could be construed to show a cardio-protective effect, but the populations studied are different, and the time course for ustekinumab treatment too short for a definitive conclusion. What can be said is that patients who developed major adverse cardiovascular events in the pivotal trials of IL-12/23 antagonists analyzed by Reich et al4 had numerous risk factors such as hypertension, diabetes, hyperlipidemia, smoking, and others. Additional caution in patients with multiple cardiovascular risk factors is therefore warranted.

Regarding conflicts of interest mentioned in the commentary,2 consultants and investigators for biological drugs should know more about those drugs than others, so it is only natural for them to report findings such as those presented in the JAMA article.1 I have been a consultant and investigator for all of the companies currently making approved biological agents for psoriasis. Ustekinumab is the only IL-12/23 antagonist approved for psoriasis. At my request, the amount that I am paid for each consultation I do for Janssen Biotech, the maker of ustekinumab, is limited to $1 to avoid the appearance of a conflict of interest for our most expensive psoriasis drug, one that is unaffordable to many patients who need it. The funds received from clinical trials are paid to my employer and do not affect my personal income.

Mark Lebwohl, MD

Author Affiliation: Department of Dermatology, Mount Sinai School of Medicine, New York, New York.

Correspondence: Dr Lebwohl, Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th St, 5th floor, New York, NY 10029-6574 (Lebwohl@aol.com).

Conflict of Interest Disclosures: Dr Lebwohl has served as consultant and investigator for Abbott Laboratories, Amgen, and Janssen Biotech.


VIGNETTES

Metastatic Adenocarcinoma From the Lung Diagnosed by Presenting Sign of a Hemangioma-Like Cutaneous Lesion

Cutaneous metastases from internal malignant neoplasms are uncommon, and the clinical manifestations have variable presentations.1 Of these, telangiectatic lesion is rare; just 1 case of a telangiectatic cutaneous lesion from adenocarcinoma of the lung was found.2 Usually, there is a long time lag between the diagnosis of the primary malignant neoplasm and the recognition of the cutaneous metastasis. However, it may be the first indication of a clinically silent internal malignant neoplasm, as in our case. We describe a patient with a unilateral hemangioma-like manifestation, which led to detection of metastatic adenocarcinoma from lung.

Report of a Case. A 61-year-old Korean man was seen for dark red lesions on the left axilla. The lesions were first observed 2 months earlier and had grown steadily. He was in good general health and did not complain of cough, dyspnea, anorexia, general weakness, or weight...